Technology
The Zurich Startup You Need to Know: Why SolidChain's Blockchain Supply-Chain Play Is Drawing $47M in Fresh Capital
A three-year-old venture based in the Europaallee district has cracked a problem that's eluded Silicon Valley-real-time pharmaceutical traceability at scale.
How we reported this
Walk into the SolidChain offices on Europaallee, and you'll notice something atypical for a blockchain company: the walls are lined with pharmaceutical packaging samples, not whitepapers. This deliberate focus on unglamorous logistics infrastructure is precisely why the startup has just closed a €43 million Series B round, led by Roche Venture Fund alongside existing backers Lakestar and Backed VC.
Founded in 2023 by former ETH researchers and a Novartis supply-chain veteran, SolidChain solves a deceptively complex problem: tracking pharmaceutical shipments across borders without creating the data silos that plague current systems. Unlike flashy Web3 projects, the company operates in the €850 billion global pharma supply-chain market-where counterfeit drugs kill an estimated 700,000 people annually, according to WHO estimates.
The timing is precise. New EU serialisation regulations, which come into full effect in 2027, mandate that every packaged medicine entering the European market carry a unique identifier. Pharmaceutical manufacturers across the continent are scrambling for solutions. SolidChain's technology sits in the unsexy middle ground between blockchain immutability and regulatory compliance-exactly where incumbents struggle.
"This is Zurich's advantage," explains the city's tech ecosystem more broadly. With Roche, Novartis, and hundreds of medtech firms headquartered here or nearby, the city has become a natural testbed for enterprise blockchain applications that actually generate revenue. Unlike previous VC cycles obsessed with token economics, 2026's funding narrative in Zurich is decidedly pragmatic: solve real problems for regulated industries, then scale.
SolidChain has already deployed pilot programs with three major European wholesalers and two multinational manufacturers. Their Series B will fund expansion into Asia-Pacific-a region where grey-market pharmaceuticals cost governments an estimated $37 billion annually in wasted healthcare spend.
The broader lesson: Zurich's startup ecosystem is increasingly defined not by hype, but by proximity to anchor tenants and regulatory expertise. The city's venture funding tripled between 2021 and 2025, but the quality of capital has shifted decisively away from consumer apps toward deep-tech solutions that serve existing industries. SolidChain exemplifies this maturation-it's the kind of company that won't dominate headlines or TechCrunch, but could quietly reshape how the world's most critical supply chains operate.
Watch this space, particularly as competing solutions from larger players emerge. For now, Europaallee's best-kept startup is quietly building the infrastructure for trustworthy medicine delivery.